# A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

> **NCT06655324** · PHASE1 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 250 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** V350A
- **BIOLOGICAL:** V350B
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06655324
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2028-07-17
- **Final completion:** 2028-07-17
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06655324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06655324, "A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06655324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*